Literature DB >> 7638647

The validity of using health state indexes in measuring the consequences of traffic injury for public health.

R Elvik1.   

Abstract

This paper describes an assessment of the validity of using health state indexes as a means of describing the consequences of traffic injury for public health. Three issues are discussed: (1) Can questionnaire data be used as input for estimating health state values by means of health state indexes? (2) Can the validity of describing the consequences of traffic injury by means of different health state indexes (QALY-indexes) be assessed? (3) Can estimated health state values be used directly as a basis for decision making? It is concluded that questionnaire data can be used as input of health state value estimation. Four health state indexes are compared: The Quality of Well Being Scale, The McMaster Health Classification System, The Rosser and Kind Index and the EuroQol Instrument (transformed version). It is concluded that an assessment of the validity of these indexes is possible, and that the EuroQol Instrument appears to be the most valid of the four indexes that are compared. None of the four indexes give values that are consistent with public policy objectives, but objectives were not set with the benefit of knowing the relative utility loss associated with injuries at different levels of severity.

Mesh:

Year:  1995        PMID: 7638647     DOI: 10.1016/0277-9536(94)00264-t

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  6 in total

1.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Cost-value analysis of health interventions: introduction and update on methods and preference data.

Authors:  Erik Nord
Journal:  Pharmacoeconomics       Date:  2015-02       Impact factor: 4.981

3.  Transforming EQ-5D utilities for use in cost–value analysis of health programs.

Authors:  Erik Nord; Rune Johansen
Journal:  Eur J Health Econ       Date:  2015-04

4.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

5.  Use of the EuroQoL among elderly acute care patients.

Authors:  J Coast; T J Peters; S H Richards; D J Gunnell
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

6.  How do Zimbabweans value health states?

Authors:  Jennifer Jelsma; Kristian Hansen; Willy De Weerdt; Paul De Cock; Paul Kind
Journal:  Popul Health Metr       Date:  2003-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.